# AstraZeneca Says Experimental Stomach Cancer Drug Doubled Survival

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/40597
Published: 2026-10-25T16:30:01.000Z
Updated: 2026-10-25T16:30:01.000Z
Section: Business

> The company identified sonesitatug vedotin as the experimental treatment in a late-stage study.

A late-stage study found twice the survival time with AstraZeneca’s experimental stomach cancer drug sonesitatug vedotin, the company said.